Saxol
Created in 2024
- BETA
To investigate (B)
Some signals may appear as inconsistent with a regular activity Social networks
637Activities
Technologies
Entity types
Location
Grenoble, France
Grenoble
France
Employees
Scale: 2-10
Estimated: 1
Engaged corporates
4
3 2Added in Motherbase
2 months ago
deeptech Value proposition
Neuroprotecting Patient's Future
Saxol, newborn company develops innovative compounds able to fight and/or to prevent peripheral neuropathies, including Diabetes peripheral neuropathies, Immuno and Chemotherapy-Induced Peripheral Neuropathies (CIPN). Based on IAB research on Carbazole structure (Lafanechère Team) and with the support of Linksium, we plan to bring to patients, new neuroprotective drugs to answers current Unmet Medical needs
CARBA1, our lead compound, has a dual pharmacological activity. 1
CARBA1 has neuroprotective activity through a mechanism of regulation and reactivation of energy production at the cellular level. 2. It enhances the action of chemotherapies, especially those based on taxane, achieving the same effectiveness with lower doses.
We plan first to develop Carba1 for CIPN Unmet Medical Need and to enlarge after to Diabetes Peripheral Neuropathy DPN and other PN
#CIPN # DPN #Pain #Nerve #Neuropathicpain #Chemotherapy #Cancer # Diabetes #Peripheralneuropathy #Burning #Unmetmedicalneed #Immunotherapy
oncology, neuropathies, peripheral neuropathies, chemotherapies, drug development, pharmaceuticals, CIPN, Diabetes, neuroprotection, Small molecule, immunotherapies, and neuronsOriginal language
Neuroprotecting Patient's Future
Saxol, newborn company develops innovative compounds able to fight and/or to prevent peripheral neuropathies, including Diabetes peripheral neuropathies, Immuno and Chemotherapy-Induced Peripheral Neuropathies (CIPN). Based on IAB research on Carbazole structure (Lafanechère Team) and with the support of Linksium, we plan to bring to patients, new neuroprotective drugs to answers current Unmet Medical needs
CARBA1, our lead compound, has a dual pharmacological activity. 1
CARBA1 has neuroprotective activity through a mechanism of regulation and reactivation of energy production at the cellular level. 2. It enhances the action of chemotherapies, especially those based on taxane, achieving the same effectiveness with lower doses.
We plan first to develop Carba1 for CIPN Unmet Medical Need and to enlarge after to Diabetes Peripheral Neuropathy DPN and other PN
#CIPN # DPN #Pain #Nerve #Neuropathicpain #Chemotherapy #Cancer # Diabetes #Peripheralneuropathy #Burning #Unmetmedicalneed #Immunotherapy
Accueil - SAXOL, the deeptech startup dedicated to neuroprotection
https://saxol.eu/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 17 Nov 2024 | | |
 MEDICALPS Business Consulting and Services | MEDICALPS Business Consulting and Services | Other 16 Apr 2024 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 20 Jun 2024 | | |
 Linksium Venture Capital and Private Equity Principals | Linksium Venture Capital and Private Equity Principals | Other 17 Nov 2024 | | |